Phenotypic screening in cancer drug discovery — past, present and future
The DOI matches its Crossref record; 181 of the 182 references it cites were found in a registry or an index.
Abstract
There has been a resurgence of interest in the use of phenotypic screens in drug discovery as an alternative to target-focused approaches. Given that oncology is currently the most active therapeutic area, and also one in which target-focused approaches have been particularly prominent in the past two decades, we investigated the contribution of phenotypic assays to oncology drug discovery by analysing the origins of all new small-molecule cancer drugs approved by the US Food and Drug Administration (FDA) over the past 15 years and those currently in clinical development. Although the majority of these drugs originated from target-based discovery, we identified a significant number whose discovery depended on phenotypic screening approaches. We postulate that the contribution of phenotypic screening to cancer drug discovery has been hampered by a reliance on 'classical' nonspecific drug effects such as cytotoxicity and mitotic arrest, exacerbated by a paucity of mechanistically defined cellular models for therapeutically translatable cancer phenotypes. However, technical and biological advances that enable such mechanistically informed phenotypic models have the potential to empower phenotypic drug discovery in oncology.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Phenotypic screening is a strategy that analyzes biology-associated (phenotypic) effects in given models such as animals, cells, or organisms to help identify the targets of candidate drugs.25,50”
From Drug repurposing for cancer therapy (2024) · cites this paper as [25]
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Network pharmacology: the next paradigm in drug discovery
Hopkins, A. L. (2008) · Nature Chemical Biology · doi:10.1038/nchembio.118 · Cited by 4,622
Selective inhibition of BET bromodomains
Filippakopoulos, P., Qi, J., Picaud, S., Shen, Y., Smith, W. B., Fedorov, O., Morse, E. M., Keates, T., Hickman, T. T., Felletar, I., et al. (2010) · Nature · doi:10.1038/nature09504 · Cited by 4,262
How to improve R&D productivity: the pharmaceutical industry's grand challenge
Paul, S. M., Mytelka, D. S., Dunwiddie, C. T., Persinger, C. C., Munos, B. H., Lindborg, S. R., & Schacht, A. L. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3078 · Cited by 3,566
How many drug targets are there?
Overington, J. P., Al-Lazikani, B., & Hopkins, A. L. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2199 · Cited by 3,505
Raise standards for preclinical cancer research
Begley, C. G., & Ellis, L. M. (2012) · Nature · doi:10.1038/483531a · Cited by 2,979
A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations
Sharma, S. V., Lee, D. Y., Li, B., Quinlan, M. P., Takahashi, F., Maheswaran, S., McDermott, U., Azizian, N., Zou, L., Fischbach, M. A., et al. (2010) · Cell · doi:10.1016/j.cell.2010.02.027 · Cited by 2,770
Targeting cancer with small molecule kinase inhibitors
Zhang, J., Yang, P. L., & Gray, N. S. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2559 · Cited by 2,576
Development of a second-generation antiandrogen for treatment of advanced prostate cancer.
Tran, C., Ouk, S., Clegg, N. J., Chen, Y., Watson, P. A., Arora, V., Wongvipat, J., Smith-Jones, P. M., Yoo, D., Kwon, A., et al. (2009) · Science · doi:10.1126/science.1168175 · Cited by 2,292
Cited by
Items 201–300 of 523
Osunmakinde, C. O., Selvarajan, R., Sibanda, T., Mamba, B. B., & Msagati, T. A. M. (2018) · Viruses · doi:10.3390/v10080429 · Cited by 20
“Bioinformatics tools are playing significant roles in all fields, in medicines for the treatment and cure of some notable diseases [31,32], drug discovery and testing [39,40], microbial genome [31,32], gene discovery and therapy [31,32,41], agriculture [31,42], antibiotic resistance [43–45], alternative energy source…”
BackgroundLin, C., Wu, H., Hsu, Y., Cheng, T.-J. R., Liu, J., Huang, R.-J., Hsiao, T.-H., Wang, C.-J., Hung, P.-F., Lan, A., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01783 · Cited by 21
Ring-Shaped Microlanes and Chemical Barriers as a Platform for Probing Single-Cell Migration
Schreiber, C., Segerer, F. J., Wagner, E., Roidl, A., & Rädler, J. O. (2016) · Scientific Reports · doi:10.1038/srep26858 · Cited by 23
Roman, B. I., Ryck, T. D., Patronov, A., Slavov, S. H., Vanhoecke, B. W. A., KATRITZKY, A. R., Bracke, M., & Stevens, C. V. (2015) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2015.06.029 · Cited by 20
A statistical framework for high-content phenotypic profiling using cellular feature distributions
Pearson, Y. E., Kremb, S., Butterfoss, G. L., Xie, X., Fahs, H., & Gunsalus, K. C. (2022) · Communications Biology · doi:10.1038/s42003-022-04343-3 · Cited by 19
“Image-based cytological pro fi ling has gained signi fi cant momentum over the last two decades 1 – 3 for gauging the phenotypic impact of different treatments, inferring mechanism of action 4 – 10 , identifying signatures of disease or toxicity, and characterizing cellular heterogeneity 11 .”
Challenges and Opportunities Toward Enabling Phenotypic Screening of Complex and 3D Cell Models
Horman, S. R., Hogan, C. J., Reyes, K. D., Lo, F., & Antczak, C. (2015) · Future Medicinal Chemistry · doi:10.4155/fmc.14.163 · Cited by 24
Chemical Proteomics–Guided Discovery of Covalent Ligands for Cancer Proteins
Zhang, X., & Cravatt, B. F. (2024) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-061421-041946 · Cited by 21
Monteiro, M. V., Rocha, M., Carvalho, M. T., Freitas, I., Amaral, A. J. R., Sousa, F. L., Gaspar, V. M., & Mano, J. F. (2024) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.4c11188 · Cited by 20
Guo, Q., Luo, Y., Zhai, S., Jiang, Z., Zhao, C., Xu, J., & Wang, L. (2019) · Organic & Biomolecular Chemistry · doi:10.1039/c9ob00616h · Cited by 19
Valero, T., Baillache, D. J., Fraser, C., Myers, S. H., & Unciti‐Broceta, A. (2019) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2019.115215 · Cited by 19
García-Lozano, M. D. R., Dragoni, F., Gallego, P., Mazzotta, S., López-Gómez, A., Boccuto, A., Martínez-Cortés, C., Martínez, A. R., Pérez‐Sánchez, H., Vega‐Pérez, J. M., et al. (2023) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2023.106408 · Cited by 19
Addressing the Right Targets in Oncology: Challenges and Alternative Approaches
Stock, J. K., Jones, N. P., Hammonds, T. R., Roffey, J., & Dillon, C. (2015) · SLAS DISCOVERY · doi:10.1177/1087057114564349 · Cited by 21
Ghosh, S. K., Ganta, A., & Spanjaard, R. A. (2018) · Journal of Biomedical Science · doi:10.1186/s12929-018-0408-6 · Cited by 18
A patent review of selective CDK9 inhibitors in treating cancer
Wu, T., Wu, X., Xu, Y., Chen, R., Wang, J., Li, Z., & Bian, J. (2023) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2023.2208747 · Cited by 18
“related phenotypes, is now returning to researchers’ attention and may markedly reduce the impact of these problems [93,94].”
BackgroundFragment-Based Drug Discovery of Phosphodiesterase Inhibitors
Svensson, F., Bender, A., & Bailey, D. S. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00404 · Cited by 19
Self-citationOrganotypic Models to Study Human Glioblastoma: Studying the Beast in Its Ecosystem
Pamies, D., Zurich, M., & Härtung, T. (2020) · iScience · doi:10.1016/j.isci.2020.101633 · Cited by 19
Rational Modulator Design By Exploitation of protein–protein Complex Structures
Wichapong, K., Poelman, H., Ercig, B., Hrdinová, J., Liu, X., Lutgens, E., & Nicolaes, G. A. F. (2019) · Future Medicinal Chemistry · doi:10.4155/fmc-2018-0433 · Cited by 19
From Lab to Clinic: Success Stories of Repurposed Drugs in Treating Major Diseases
Hussain, M. S., Mir, P. A., Kumar, N., Mohi-ud-din, R., Wali, A. F., Mir, R. H., Talath, S., Sridhar, S. B., Shareef, J., Goud, M., et al. (2025) · Advances in Pharmacological and Pharmaceutical Sciences · doi:10.1155/adpp/1070716 · Cited by 23
“Traditional drug discovery mostly emphasises target-based strategies, while phenotypic screening may fnd molecules that have favourable therapeutic efects irrespective of their precise molecular targets [167].”
Catalano, M., Oehler, S., Prati, L., Favalli, N., Bassi, G., Scheuermann, J., & Neri, D. (2020) · Analytical Chemistry · doi:10.1021/acs.analchem.0c02304 · Cited by 17
Kang, D., Urhan, Ç., Wei, F., Frutos-Beltrán, E., Sun, L., Álvarez, M., Feng, D., Tao, Y., Pannecouque, C. C., Clercq, E. D., et al. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113769 · Cited by 19
An off-the-shelf multi-well scaffold-supported platform for tumour organoid-based tissues
Li, N. T., Wu, N. C., Cao, R., Cadavid, J. L., Latour, S., Lu, X., Zhu, Y., Mijalkovic, M., Roozitalab, R., Landon‐Brace, N., et al. (2022) · Biomaterials · doi:10.1016/j.biomaterials.2022.121883 · Cited by 24
Privileged Structures and Polypharmacology within and between Protein Families
Meyers, J., Chessum, N. E. A., Ali, S., Mok, N. Y., Wilding, B., Pasqua, E., Rowlands, M., Tucker, M. J., Evans, L. E., Rye, C. S., et al. (2018) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.8b00364 · Cited by 18
A Knowledge‐Guided Graph Learning Approach Bridging Phenotype‐ and Target‐Based Drug Discovery
Ye, Q., Zeng, Y., Jiang, L., Kang, Y., Pan, P., Chen, J., Deng, Y., Zhao, H., He, S., Hou, T., et al. (2025) · Advanced Science · doi:10.1002/advs.202412402 · Cited by 22
Single-cell infrared phenomics: phenotypic screening with infrared microspectroscopy
Wang, Y., Wang, Y., Qian, J., Pan, X., Li, X., Chen, F., Hu, J., & Lü, J. (2020) · Chemical Communications · doi:10.1039/d0cc05721e · Cited by 16
Shao, L., Campbell, U. C., Fang, Q. K., Powell, N. A., Campbell, J. E., JONES, P. G., Hanania, T., Alexandrov, V., Morganstern, I., Sabath, E. V., et al. (2016) · MedChemComm · doi:10.1039/c6md00128a · Cited by 16
A Large-Scale Gene Expression Intensity-Based Similarity Metric for Drug Repositioning
Huang, C.-T., Hsieh, C.-H., Oyang, Y.-J., Huang, H., & Juan, H. (2018) · iScience · doi:10.1016/j.isci.2018.08.017 · Cited by 15
“Since polypharmacology interactions that a drug might undergo within a cell should faithfully translate into cellular phenotypic responses (Feng et al., 2009; Moffat et al., 2014), similarity approaches that compare gene expression profiles after chemical perturbations are showing considerable promise, from an initial…”
BackgroundCvijetić, I., Herlah, B., Marinković, А., Perdih, A., & Bjelogrlić, S. (2023) · Pharmaceuticals · doi:10.3390/ph16030341 · Cited by 16
“Although there are successful examples of hit-to-lead optimization using ligand-based structure–activity relationships (SAR), lack of target knowledge is considered a major risk for clinical development and regulatory approval [22].”
BackgroundHigh content analysis in amyotrophic lateral sclerosis
Rinaldi, F., Motti, D., Ferraiuolo, L., & Kaspar, B. K. (2016) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2016.12.001 · Cited by 17
Zhao, H., Zhou, L., Zhang, Q., Zhou, X., Zhang, Y., Chen, H., & Du, Y. (2015) · Lab on a Chip · doi:10.1039/c5lc00589b · Cited by 16
Salame, N., Fooks, K., El-Hachem, N., Bikorimana, J., Mercier, F., & Rafei, M. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.852143 · Cited by 18
“In the case of RAS-mutant cancer, several comparative HTS screens could identify bioactive compounds tied to this genotype (Moffat et al., 2014).”
BackgroundInfluentialWang, Q., Zhang, X., Li, Q., Liu, X., Huang, Y., Cheng, S., Shinohara, H., Liu, Z., & Zhu, X. (2024) · Sensors and Actuators B Chemical · doi:10.1016/j.snb.2024.135286 · Cited by 15
Recent developments on the synthesis of biologically active glycohybrids
Mishra, V. K., Khanna, A., Tiwari, G., Tyagi, R., & Sagar, R. (2024) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2024.107172 · Cited by 20
Zaini, M. A., Müller, C., Ackermann, T., Reinshagen, J., Kortman, G., Pleß, O., & Calkhoven, C. F. (2017) · Scientific Reports · doi:10.1038/srep42603 · Cited by 15
Kunimoto, R., Dimova, D., & Bajorath, J. (2017) · ACS Omega · doi:10.1021/acsomega.7b00215 · Cited by 14
Peng, B., Yu, C., Du, S., Liew, S. S., Mao, X., Yuan, P., Na, Z., & Yao, S. Q. (2018) · ChemBioChem · doi:10.1002/cbic.201800101 · Cited by 14
The Oncopig Cancer Model as a Complementary Tool for Phenotypic Drug Discovery
Segatto, N. V., Remião, M. H., Schachtschneider, K. M., Seixas, F. K., Schook, L. B., & Collares, T. V. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00894 · Cited by 16
“In general, PDD remains a crucial approach in selecting, validating, and developing potential cancer drugs, even though it represents a minority of the investigational and recently approved oncology treatments (Moffat et al., 2014).”
BackgroundJörg, M., & Madden, K. S. (2021) · RSC Medicinal Chemistry · doi:10.1039/d1md00022e · Cited by 15
Future Directions in Pain Management
Pleticha, J., Maus, T. P., & Beutler, A. S. (2016) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2016.02.015 · Cited by 16
Toviwek, B., Suphakun, P., Choowongkomon, K., Hannongbua, S., & Gleeson, M. P. (2017) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2017.08.063 · Cited by 14
Pancreas Cancer Precision Treatment Using Avatar Mice from a Bioinformatics Perspective
Perales-Patón, J., Piñeiro-Yáñez, E., Tejero, H., Lopez-Casas, P. P., Hidalgo, M. M., Goméz-López, G., & Al‐Shahrour, F. (2017) · Public Health Genomics · doi:10.1159/000479812 · Cited by 16
“In cancer, different studies have shown that by using drug libraries [43] or by computational approaches [44] , new antitumor activities have been found for known drugs already used for other diseases.”
BackgroundCurrent trends and future prospects of drug repositioning in gastrointestinal oncology
Fatemi, N., Karimpour, M., Bahrami, H., Zali, M. R., Chaleshi, V., Riccio, A., Mojarad, E. N., & Totonchi, M. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1329244 · Cited by 19
“Phenotypic screening, a direct method of DR, involves identifying compounds based on their effects in model systems without prior knowledge of candidate drug targets (Moffat et al., 2014, 2017; Kim et al., 2019).”
MethodLabel-free technologies for target identification and validation
Li, J., Xu, H., West, G. M., & Jones, L. H. (2016) · MedChemComm · doi:10.1039/c6md00045b · Cited by 13
A new parameter of growth inhibition for cell proliferation assays
Fiorentino, F. P., Bagella, L., & Marchesi, I. (2017) · Journal of Cellular Physiology · doi:10.1002/jcp.26208 · Cited by 13
“In anticancer drug development, they are used to evaluate the anti-proliferative activity of tested compounds on established tumor cell lines, primary tumor cells and 3D tumor organoids (Adan et al., 2016; Finlay and Baguley, 1984; Horvath et al., 2016; Moffat et al., 2014; Boyd:1992ht Rello-Varona et al., 2015; Selby…”
BackgroundUrasaki, Y., Fiscus, R. R., & Le, T. T. (2018) · Scientific Reports · doi:10.1038/s41598-018-28335-8 · Cited by 13
An, S., Yu, J., Choi, H., Ko, H., Ahn, S., Shin, J. C., Pyo, J. J., Jeong, L. S., & Noh, M. (2019) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2019.115226 · Cited by 13
Linking chemicals, genes and morphological perturbations to diseases
Cerisier, N., Dafniet, B., Badel, A., & Taboureau, O. (2023) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2023.116407 · Cited by 17
Saidel, M. É., dos Santos, K. C., Nagano, L. F. P., Montanari, C. A., & Leitão, A. (2017) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2017.07.061 · Cited by 13
Jiang, J.-H., Zhang, Q., Guo, J., Fang, S., Zhou, R., Zhu, J., Chen, X., Zhou, Y., & Zheng, C. (2019) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2019.07.042 · Cited by 13
Glycohybrid molecules in medicinal chemistry: Present status and future prospective
Kumari, P., Narayana, C., Tiwari, G., & Sagar, R. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-816675-8.00011-7 · Cited by 14
Fragment-Based Phenotypic Lead Discovery To Identify New Drug Seeds That Target Infectious Diseases
Ayotte, Y., Bernet, È., Bilodeau, F., Cimino, M., Gagnon, D., Lebughe, M., Mistretta, M., Ogadinma, P., Ouali, S.-L., Sow, A. A., et al. (2021) · ACS Chemical Biology · doi:10.1021/acschembio.1c00657 · Cited by 12
Sakai, T. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108234 · Cited by 13
O’Brien, N. S., Gilbert, J., McCluskey, A., & Sakoff, J. A. (2024) · RSC Medicinal Chemistry · doi:10.1039/d3md00600j · Cited by 15
Xin, X., Wu, Y., Zang, R., & Yang, S. (2018) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2018.11.018 · Cited by 13
Maguire, G., Paler, L., Green, L., Mella, R. M., Valcárcel, M., & Villacé, P. (2019) · Physiological Reports · doi:10.14814/phy2.14072 · Cited by 13
“2014), therapeutic development must also bring physiology “centre stage” (Moffat et al. 2014) given that genomics centric therapeutic development strategies, having forgotten physiology (Viney 2014), has failed to bring successful therapeutics to the market over the last two decades of genome-centric research and deve…”
BackgroundLiang, T., Guan, R., 曹国洲, Shen, H., Liu, Z., 夏其乐, & Wang, Z. (2019) · Journal of Food Science · doi:10.1111/1750-3841.14629 · Cited by 12
Ji, K., Sameni, M., Osuala, K. O., Moin, K., Mattingly, R. R., & Sloane, B. F. (2019) · Cancer and Metastasis Reviews · doi:10.1007/s10555-019-09810-8 · Cited by 13
Autonome Entdeckung in den chemischen Wissenschaften, Teil I: Fortschritt
Coley, C. W., Eyke, N. S., & Jensen, K. F. (2019) · Angewandte Chemie · doi:10.1002/ange.201909987 · Cited by 12
Orphan diseases: state of the drug discovery art
Volmar, C., Wahlestedt, C., & Brothers, S. P. (2016) · Wiener Medizinische Wochenschrift · doi:10.1007/s10354-015-0423-0 · Cited by 12
MITF suppression by CH5552074 inhibits cell growth in melanoma cells
Aida, S., Sonobe, Y., Yuhki, M., Sakata, K., Fujii, T., Sakamoto, H., & Mizuno, T. (2017) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-017-3317-6 · Cited by 14
“Although some potent therapeutics, such as trametinib, that were identified in a cell-based phenotypic screen have been approved and utilized in clinic [19, 20], the difficulty of identifying the target molecule of compounds obtained by this approach remains as a major hurdle in drug development.”
BackgroundChen, T., Sun, T., Bian, Y., Pei, Y., Feng, F., Chi, H., Li, Y., Tang, X., Sang, S., Du, C., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01456 · Cited by 11
Herbst, S. A., Kim, V., Roider, T., Schitter, E. C., Bruch, P., Liebers, N., Kolb, C., Knoll, M., Lu, J., Dreger, P., et al. (2023) · Blood Advances · doi:10.1182/bloodadvances.2022009652 · Cited by 11
“Therefore, stroma-leukemia coculture models are considered a potential ex vivo platform to profile drug responses of tumor cells while mimicking the interactive effects of the microenvironment [10, 20, 25-27].”
Oxidation states in metallocenes: A key mechanistic component in cancer alleviation
Das, R., Chatterjee, D. R., & Shard, A. (2024) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2024.215666 · Cited by 14
Soliman, A. M., El-sagheir, A. M. K., Thabet, M. M., Hakiem, A. F. A., & Aboraia, A. S. (2024) · Drug Development Research · doi:10.1002/ddr.22156 · Cited by 11
Cyclodextrin-Based Nanogels for Stabilization and Sensing of Curcumin
Casulli, M. A., Yan, R., Takeuchi, S., Cesari, A., Mancin, F., Hayashita, T., Hashimoto, T., & Taurino, I. (2024) · ACS Applied Nano Materials · doi:10.1021/acsanm.4c02972 · Cited by 11
Advances in the Repurposing and Blood–Brain Barrier Penetrance of Drugs in Pediatric Brain Tumors
Rechberger, J. S., Toll, S. A., Biswas, S., You, H. B., Chow, W. D., Kendall, N. A. S., Navalkele, P. D., & Khatua, S. (2025) · Cancers · doi:10.3390/cancers17030439 · Cited by 14
“However, it was only recently that the con‑ cept of repurposing has been developed strategically with technological advances [37,38].”
Cunningham, R., Jia, S., Purohit, K. P., Nosková, M., Maniak, M. K., Lin, Y., Hui, N. S., Graham, R. E., Rossi, A. G., Cholewa-Waclaw, J., et al. (2025) · Life Science Alliance · doi:10.26508/lsa.202503241 · Cited by 13
“Conventional phenotypic screening approaches, which typically gauge success based on the cytotoxic or cytostatic properties of therapeutics, are impeded by their limited scope and are biased to drugs with broad toxicity profiles (93).”
Approaches for discovering novel bioactive small molecules targeting autophagy
Hwang, H., Cho, S. M., & Kwon, H. J. (2017) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2017.1349751 · Cited by 13
Kaczmarczyk, J. A., Roberts, R. R., Luke, B. T., Chan, K. C., Wagoner, C. M. V., Felder, R. A., Saul, R. G., Colantonio, S., & Blonder, J. (2021) · Oncotarget · doi:10.18632/oncotarget.28072 · Cited by 12
“Typically, preclinical assessment of drug effectiveness relies on functional cell assays, incidental imaging procedures, and histopathological examinations.[10] To better understand and standardize results obtained in the preclinical phase, it is of prime interest to better characterize”
BackgroundPartnerships for better neglected disease drug discovery and development: how have we fared?
Sunyoto, T. (2020) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2020.1736550 · Cited by 11
Lovrics, A., Pape, V. F. S., Szisz, D., Kalászi, A., Heffeter, P., Magyar, C., & Szakács, G. (2019) · Journal of Cheminformatics · doi:10.1186/s13321-019-0390-3 · Cited by 11
Milenković, U., Ilg, M. M., Cellek, S., & Albersen, M. (2019) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2019.1591370 · Cited by 12
Vellaiyan, V., Allaka, T. R., Bhoomandla, S., Vudari, B., Chepuri, K., & Nagarajaiah, H. (2024) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2024.141189 · Cited by 10
HDAC specificity and kinase off-targeting by purine-benzohydroxamate anti-hematological tumor agents
Waitman, K. B., de Almeida, L. C., Primi, M. C., Carlos, J. A. E. G., Ruiz, C. H., Kronenberger, T., Laufer, S., Goettert, M. I., Poso, A., Vassiliades, S. V., et al. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115935 · Cited by 10
Kremer, L., Schultz‐Fademrecht, C., Baumann, M., Habenberger, P., Choidas, A., Klebl, B., Kordes, S., Schöler, H. R., Sterneckert, J. L., Ziegler, S., et al. (2017) · Angewandte Chemie · doi:10.1002/ange.201707394 · Cited by 10
Transcriptomics-Based Phenotypic Screening Supports Drug Discovery in Human Glioblastoma Cells
Shapovalov, V., Kopanitsa, L., Pruteanu, L.-L., Ladds, G., & Bailey, D. S. (2021) · Cancers · doi:10.3390/cancers13153780 · Cited by 11
“The last decade has seen a resurgence in phenotypic screening, largely due to the realization that sifting through the thousands of potential therapeutic targets delivered from genomics, one by one, is both time-consuming and expensive [15,16].”
BackgroundSelf-citationDrug combination screening as a translational approach toward an improved drug therapy for chordoma
Scheipl, S., Barnard, M., Lohberger, B., Zettl, R., Brčić, I., Liegl‐Atzwanger, B., Rinner, B., Meindl, C., & Fröhlich, E. (2021) · Cellular Oncology · doi:10.1007/s13402-021-00632-x · Cited by 10
“have not been sufficiently covered by target-based approaches to date [33].”
BackgroundYe, Z., Chen, F., Zeng, J., Gao, J. T., & Zhang, M. Q. (2021) · Advanced Science · doi:10.1002/advs.202102092 · Cited by 11
Predicting drug-target interaction based on sequence and structure information
Lan, W., Wang, J., Li, M., Wu, F., & Pan, Y. F. (2015) · IFAC-PapersOnLine · doi:10.1016/j.ifacol.2015.12.092 · Cited by 10
Tran, T.-D., & Pham, D.-T. (2021) · Scientific Reports · doi:10.1038/s41598-021-93336-z · Cited by 11
Evans, L. E., Jones, K., & Cheeseman, M. D. (2017) · Chemical Communications · doi:10.1039/c7cc01376k · Cited by 9
Bioinformatics and Translation Elongation
Xia, X. (2018) · Springer eBooks · doi:10.1007/978-3-032-18842-7_11 · Cited by 10
Drug efficacy and toxicity prediction: an innovative application of transcriptomic data
Xia, X. (2020) · Cell Biology and Toxicology · doi:10.1007/s10565-020-09552-2 · Cited by 9
Enhancing Etoposide Aqueous Solubility and Anticancer Activity with L-Arginine
Alsalhi, A., Ayon, N. J., Coulibaly, F. S., Alshamrani, M., Alnafisah, A. S., & Youan, B.-B. C. (2021) · Assay and Drug Development Technologies · doi:10.1089/adt.2021.085 · Cited by 9
Lv, G., Shi, Q., Zhang, T., Li, J., Long, Y., Zhang, W., Choudhry, N., Yang, K., Li, H., Kalashova, J., et al. (2023) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2023.117173 · Cited by 9
Li, X., Chen, Y., Bai, L., Zhao, R., Wu, Y., Xie, Z., Wu, J. M., Bowen, N. J., Danaher, A., Cook, N., et al. (2023) · British Journal of Cancer · doi:10.1038/s41416-023-02359-y · Cited by 9
“Compared with traditional phenotypic screens, MIPDD can provide a more efficient approach to discovering new drugs with optimal mechanisms of action for treating advanced and therapeutically resistant cancers [11].”
BackgroundTian, X., Zhang, S., Su, Y., Huang, W., Zhang, Y., Ma, X., Li, K., Lv, X., Chen, C., & Chen, C. (2024) · Applied Soft Computing · doi:10.1016/j.asoc.2024.111898 · Cited by 10
Enantioselective protein affinity selection mass spectrometry (E-ASMS)
Wang, X., Sun, J., Ahmad, S., Yang, D., Li, F., Chan, U. H., Zeng, H., Simoben, C. V., Green, S. R., Silva, M., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-67403-2 · Cited by 18
Implementation and Use of State-of-the-Art, Cell-Based In Vitro Assays
Langer, G. (2015) · Handbook of experimental pharmacology · doi:10.1007/164_2015_18 · Cited by 12
Simpson, D. H., & Scott, P. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-803814-7.00007-1 · Cited by 11
Deng, Y., Pi, R., Niu, L., Zhao, Y., Ni, D., Song, L., Li, Z., Han, W., Wei, Q., Han, Y., et al. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.114010 · Cited by 9
Recent advances in quantitative high throughput and high content data analysis
Moutsatsos, I. K., & Parker, C. N. (2016) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2016.1154036 · Cited by 10
“[41 ] High-content screening (HCS), which allows the high-throughput imaging and measurement of different parameters at the single-cell level, is the most commonly used form of image-based screening.”
BackgroundWang, Y., Wu, Y., Chen, Y., Zhang, J., Chen, X., & Liu, P. (2018) · Micromachines · doi:10.3390/mi9060286 · Cited by 9
“High-throughput cell-based assays have become an indispensable workhorse for discovering new drug candidates [1,2], deciphering complicated cellular processes [3,4], annotating gene functions [5], etc.”
BackgroundAnticancer Effects of Constituents of Herbs Targeting Osteosarcoma
Su, Q., Xu, X., Wang, J., Luan, J., Ren, X., Huang, H., & Bian, S.-S. (2019) · Chinese Journal of Integrative Medicine · doi:10.1007/s11655-019-2941-x · Cited by 9
A Drosophila Based Cancer Drug Discovery Framework
Bangi, E. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-23629-8_14 · Cited by 9
Lahue, B. R., Glick, M., Tudor, M., Johnson, S. A., Diratsouian, J., Wildey, M. J., Burton, M. S., Mazzola, R., & Wassermann, A. M. (2019) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2019.115192 · Cited by 9
Xie, H., Yang, K., Winston‐McPherson, G. N., Stapleton, D. S., Keller, M. P., Attie, A., Smith, K. A., & Tang, W. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112678 · Cited by 10
Xu, D. D., Zhou, D., Bum‐Erdene, K., Bailey, B. J., Sishtla, K. L., Liu, S., Wan, J., Aryal, U. K., Lee, J. A., Wells, C. D., et al. (2020) · ACS Chemical Biology · doi:10.1021/acschembio.0c00078 · Cited by 8
Phenotypic Identification of a Novel Autophagy Inhibitor Chemotype Targeting Lipid Kinase VPS34
Robke, L., Laraia, L., Corrales, M. A. C., Konstantinidis, G., Muroi, M., Richters, A., Winzker, M., Engbring, T., Tomassi, S., Watanabe, N., et al. (2017) · Angewandte Chemie · doi:10.1002/ange.201703738 · Cited by 8
Zhao, X., Zhong, C., Zhu, R., Gong, R., Liu, B., He, L., Tian, S., Jin, J., Jiang, T., Chen, J., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c01484 · Cited by 8
High content analysis of phagocytic activity and cell morphology with PuntoMorph
Al‐Ali, H., Gao, H., Hansen, C. D., Peters, V. A., Shi, Y., & Brambilla, R. (2017) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2017.08.004 · Cited by 8
Metadata
- Authors
- Moffat, J. G., Rudolph, J., & Bailey, D.
- Affiliations
- Genentech (US)
- Corresponding author
- Moffat, John G.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2014-07-18
- Volume
- 13
- Issue
- 8
- Pages
- 588-602
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2123059506
- Semantic Scholar
- 1042a4c884176fac046b7c6751c953ed949f8066
- Cited by
- 507
- References
- 182
- Citations by year
- 2026: 28 · 2025: 37 · 2024: 43 · 2023: 30 · 2022: 36 · 2021: 48 · 2020: 45 · 2019: 48 · 2018: 52 · 2017: 56 · 2016: 42 · 2015: 39 · 2014: 3
- FWCI
- 3.85
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Funders
- U.S. Food and Drug Administration
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Mechanisms and Therapy
- Keywords
- phenotypic screening, anticancer drug discovery, anticancer drug development, small molecule anticancer agents, FDA-approved anticancer drugs, target-based drug discovery, cytotoxicity, mitotic arrest
- MeSH terms
- Antineoplastic Agents, Drug Screening Assays, Antitumor, Forecasting, Humans, Neoplasms, Phenotype, History, 20th Century, History, 21st Century, Drug Discovery
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.